Trials / Completed
CompletedNCT06990347
A Study on the Efficacy and Safety of IPyC for HER2+ MBC
A Retrospective Multicenter Cohort Study on the Efficacy and Safety of Inetetamab and Pyrotinib Combined With Chemotherapy for HER2-positive Metastatic Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 301 (actual)
- Sponsor
- Fujian Medical University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
Between July 2020 and August 2024, 301 HER2-positive MBC patients from five tertiary centers received the regimen until disease progression or unacceptable toxicity. Efficacy endpoints included progression-free survival (PFS), objective response rate (ORR), and clinical benefit rate (CBR).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inetetamab and Pyrotinib Combined with Chemotherapy | Inetetamab and Pyrotinib Combined with Chemotherapy |
Timeline
- Start date
- 2020-07-01
- Primary completion
- 2024-08-01
- Completion
- 2025-05-01
- First posted
- 2025-05-25
- Last updated
- 2025-05-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06990347. Inclusion in this directory is not an endorsement.